Holen Sie sich die Stockscreener-App
0.9674
8.74%
-0.0926
Schlusskurs vom Vortag:
$1.06
Offen:
$1.065
24-Stunden-Volumen:
8.31M
Relative Volume:
0.78
Marktkapitalisierung:
$94.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+17.32%
1M Leistung:
-83.96%
6M Leistung:
-67.43%
1J Leistung:
-56.62%
1-Tages-Spanne:
$0.95
$1.08
1-Wochen-Bereich:
$0.7995
$1.12
52-Wochen-Spanne:
$0.6816
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.9674 | 103.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-05 | Eingeleitet | Jefferies | Buy |
| 2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-10 | Eingeleitet | Laidlaw | Buy |
| 2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Eingeleitet | Citigroup | Neutral |
| 2015-06-01 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
Detecting support and resistance levels for aTyr Pharma Inc.2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
What catalysts could drive aTyr Pharma Inc. stock higherQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
Is aTyr Pharma Inc. (471A) stock among top earnings playsEarnings Miss & Community Supported Trade Ideas - newser.com
Will aTyr Pharma Inc. outperform the market2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Statistical indicators supporting aTyr Pharma Inc.’s strengthRate Cut & Community Trade Idea Sharing - newser.com
Why aTyr Pharma Inc. stock could see breakout soonStock Surge & Scalable Portfolio Growth Ideas - newser.com
Levi & Korsinsky Urges aTyr Pharma, Inc. (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - ACCESS Newswire
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - ACCESS Newswire
ATYR LAWSUIT ALERT: Levi & Korsinsky Notifies aTyr Pharma, Inc. InvestorsLead Plaintiff Deadline December 8, 2025 - ACCESS Newswire
aTyr Pharma Sees Significant Rebound in Premarket Trading - timothysykes.com
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - ACCESS Newswire
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Business Wire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Insider Spends US$912k Buying More Shares In ATyr Pharma - 富途牛牛
Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares - Yahoo Finance
What makes aTyr Pharma Inc. (471A) stock appealing to growth investorsWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Measuring aTyr Pharma Inc.’s beta against major indices2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
aTyr Pharma Rebounds with 7.4% Premarket Surge After Recent Decline - StocksToTrade
ATyr Pharma Faces Investor Suit Over Failed Drug Trial - Law360
Insider Buying: aTyr Pharma (NASDAQ:ATYR) Director Purchases 682,001 Shares of Stock - MarketBeat
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc. - GlobeNewswire Inc.
ATyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - MarketScreener
aTyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - The Globe and Mail
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The AI Journal
Levi & Korsinsky Invites Investors to SueWallSt After aTyr Pharma, Inc. Stock Collapse - ACCESS Newswire
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - FinancialContent
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline - GlobeNewswire
Published on: 2025-10-10 09:51:10 - newser.com
aTyr Pharma, Inc. Stock (ATYR) Opinions on Phase 3 Trial Failure - Quiver Quantitative
Trend analysis for aTyr Pharma Inc. this weekJuly 2025 Levels & Technical Buy Zone Confirmations - newser.com
aTyr Pharma Faces Legal Storm After Trial Failure - TipRanks
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - MSN
What to expect from aTyr Pharma Inc. in the next 30 days2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
Why aTyr Pharma Inc. (471A) stock appears on watchlistsEntry Point & Community Verified Trade Signals - newser.com
Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company - Eastern Progress
Director Makes Major Investment in aTyr Pharma! - TipRanks
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit — Hagens Berman - The Malaysian Reserve
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman - PR Newswire
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After - GlobeNewswire
Atyr pharma director Schimmel buys shares worth $911k By Investing.com - Investing.com UK
Atyr pharma director Schimmel buys shares worth $911k - Investing.com India
aTyr Pharma (NASDAQ:ATYR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
aTyr Pharma Investor Sues Over Drug Study’s Endpoint Miss (1) - Bloomberg Law News
Is aTyr Pharma Inc a good long term investmentMarket Timing Techniques & Small Investment Trading Growth - earlytimes.in
Can aTyr Pharma Inc. (471A) stock sustain revenue momentumTrade Entry Report & Verified Entry Point Signals - newser.com
Evaluating aTyr Pharma Inc. with trendline analysisJuly 2025 Recap & Community Verified Trade Signals - newser.com
Why aTyr Pharma Inc. (471A) stock is favored by hedge funds2025 Institutional Moves & Weekly High Potential Alerts - newser.com
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Atyr Pharma Inc-Aktie (ATYR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):